Recently, the China Drug Administration approved the marketing of the Class 1 innovative drug, etripamil nasal spray, declared by Milestone Pharmaceuticals Inc. This drug is used to treat acute attacks of paroxysmal supraventricular tachycardia in adults, which reverted to sinus rhythm. The launch of this drug provides patients with new treatment options.

Recently, the China Drug Administration approved the marketing of the Class 1 innovative drug, etripamil nasal spray, declared by Milestone Pharmaceuticals Inc. This drug is used to treat acute attacks of paroxysmal supraventricular tachycardia in adults, which revert to sinus rhythm. The launch of this drug provides patients with new treatment options.